Description of the drug RINZASIP®
Paracetamol
Enhances the effects of MAO inhibitors, sedatives, ethanol.
The risk of hepatotoxic action of paracetamol increases with simultaneous use of barbiturates, phenytoin, phenobarbital, carbamazepine, rifampicin, isoniazid, zidovudine and other inducers of microsomal liver enzymes.
With long-term regular use of paracetamol, the anticoagulant effect of warfarin and other coumarins may be enhanced, and the risk of bleeding increases. A single use of paracetamol does not have a significant effect.
Metoclopramide increases the rate of absorption of paracetamol and reduces the time to reach its Cmax in the blood plasma. Likewise, domperidone may increase the rate of absorption of paracetamol.
Paracetamol may lead to an increase in T1/2 of chloramphenicol.
Paracetamol can reduce the bioavailability of lamotrigine, which may reduce the effectiveness of lamotrigine due to the induction of its metabolism in the liver.
Absorption of paracetamol may be reduced when used concomitantly with cholestyramine, but the reduction in absorption is not significant if cholestyramine is taken one hour later.
Regular use of paracetamol concomitantly with zidovudine may cause neutropenia and increase the risk of liver damage.
Probenecid affects the metabolism of paracetamol. In patients concomitantly using probenecid, the dose of paracetamol should be reduced.
The hepatotoxicity of paracetamol increases with prolonged excessive consumption of ethanol (alcohol).
Paracetamol may interfere with the results of the uric acid test using the phosphotungstate precipitating reagent.
Pheniramine
The effect of other substances on the central nervous system (for example, MAO inhibitors, tricyclic antidepressants, alcohol, antiparkinsonian drugs, barbiturates, tranquilizers and narcotic drugs) may be enhanced. Pheniramine may inhibit the action of anticoagulants.
Phenylephrine
Phenylephrine can potentiate the effect of MAO inhibitors and cause a hypertensive crisis.
Concomitant use of phenylephrine with other sympathomimetic drugs or tricyclic antidepressants (eg, amitriptyline) may lead to an increased risk of adverse cardiovascular reactions.
Phenylephrine may reduce the effectiveness of beta blockers and other antihypertensive drugs (eg, debrisoquine, guanethidine, reserpine, methyldopa). There may be an increased risk of hypertension and other cardiovascular side effects.
Concomitant use of phenylephrine with digoxin and cardiac glycosides may increase the risk of cardiac arrhythmias or myocardial infarction.
Concomitant use of phenylephrine with ergot alkaloids (ergotamine and methysergide) may increase the risk of ergotism.
When used simultaneously with barbiturates and primidone, the excretion of ascorbic acid in the urine increases.
Caffeine
Caffeine accelerates the absorption of ergotamine.
Rinzasip®
In case of overdose, consult a doctor immediately.
Prompt medical attention is critical, even if you do not experience any signs or symptoms.
Caffeine
Symptoms of acute overdose: abdominal pain, vomiting, feeling of heat, facial flushing, fever, chills, agitation, insomnia, irritability, loss of appetite, weakness, tremor, increased muscle tone, state of altered consciousness, delirium, hallucinations, increased blood pressure followed by arterial hypotension, tachycardia, tachypnea, increased diuresis, hypokalemia, hyponatremia, hyperglycemia, metabolic acidosis, convulsions, myoclonus and rhabdomyolysis, supraventricular and ventricular arrhythmias.
Symptoms of chronic caffeine intoxication, “caffeineism”: irritability, insomnia, anxiety, emotional lability, chronic abdominal pain.
Pheniramine
Symptoms: central nervous system depression, hyperthermia, anticholinergic syndrome (mydriasis, flushing, fever, dry mouth, urinary retention, intestinal paresis), tachycardia, arterial hypotension, arterial hypertension, nausea, vomiting, agitation, disorientation, hallucinations, psychosis, convulsions, arrhythmias. Rarely, patients with agitation, seizures, or comatose patients develop rhabdomyolysis and renal failure.
Phenylephrine
Symptoms: nausea, vomiting, irritability, agitation, insomnia, psychosis, convulsions, palpitations, tachycardia, increased blood pressure, reflex bradycardia.
Paracetamol
Symptoms appear after taking more than 7.5-10 g: during the first 24 hours after taking - pale skin, nausea, vomiting; anorexia, abdominal pain; increased prothrombin time, impaired glucose metabolism, hypokalemia and metabolic acidosis (including lactic acidosis).
Symptoms of liver dysfunction may appear 12-48 hours after an overdose: increased activity of “liver” transaminases, hepatonecrosis. In severe cases - liver failure with progressive encephalopathy, coma. Rarely, liver failure develops rapidly and can be complicated by renal failure (tubular necrosis).
Treatment: gastric lavage, administration of activated carbon in the first 6 hours after an overdose, administration of SH-group donors and precursors for the synthesis of glutathione - methionine 8-9 hours after an overdose and acetylcysteine after 12 hours. The need for additional therapeutic measures (further administration of methionine and acetylcysteine) is determined by the concentration of paracetamol in the blood, as well as the time elapsed after its administration. Symptomatic therapy.
The threshold for overdose may be lowered in elderly patients and children, in patients taking certain medications (eg, liver microsomal enzyme inducers), alcohol, or who are malnourished.
Rinzasip with vitamin C powder for preparing a solution with lemon flavor, 5 g 5 pcs.
Registration Certificate Holder
JOHNSON & JOHNSON (Russia)
Dosage form
Medicine - Rinzasip® with vitamin C (Rinzasip® with vitamin C)
Description
Powder for oral solution (lemon)
from light yellow to yellow with white and yellow splashes.
1 sachet
ascorbic acid (vit. C) 200 mg caffeine 30 mg paracetamol 750 mg pheniramine maleate 20 mg phenylephrine hydrochloride 10 mg
Excipients
: citric acid - 200 mg, sodium saccharinate - 40 mg, sodium citrate - 500 mg, sucrose - 3136 mg, quinoline yellow dye (E104) - 1 mg, lemon flavor - 83 mg.
5 g - sachets made of laminated aluminum foil (5) - cardboard packs. 5 g - sachets made of laminated aluminum foil (10) - cardboard packs.
Indications
- symptomatic treatment of colds, flu, acute respiratory viral infections (fever, pain, rhinorrhea).
Contraindications for use
- hypersensitivity to individual components of the drug, as well as to sympathomimetic drugs;
- simultaneous use of medications containing substances included in the drug;
- severe atherosclerosis of the coronary arteries;
- portal hypertension;
- conditions associated with the accumulation of iron in the body, such as hemochromatosis;
- severe renal failure or hemodialysis;
- simultaneous use of tricyclic antidepressants, beta-blockers, MAO inhibitors and discontinuation of their use less than 2 weeks ago;
- alcoholism;
- sucrase/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption;
- pregnancy;
- lactation period (breastfeeding);
- children under 15 years of age.
With caution
For heart disease, arterial hypertension, bronchial asthma, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, thyroid diseases, diabetes mellitus, pheochromocytoma, blood diseases, glucose-6-phosphate dehydrogenase deficiency, acute hepatitis, congenital hyperbilirubinemia (Gilbert's syndrome, Dubin-Johnson and Rotor), liver and/or renal failure, concomitant use of drugs that can adversely affect the liver (for example, inducers of microsomal liver enzymes), pyloroduodenal obstruction, stenosing gastric and/or duodenal ulcer, angle-closure glaucoma, epilepsy, hyperplasia prostate, urolithiasis, with the formation of kidney stones, as well as in patients suffering from exhaustion and/or dehydration, the drug can be used with caution after consultation with a doctor.
pharmachologic effect
The combined drug has antipyretic, analgesic, alpha-adrenergic stimulating, vasoconstrictor and antihistamine effects, eliminating the symptoms of “colds”.
Paracetamol -
non-narcotic analgesic; blocks cyclooxygenase, mainly in the central nervous system, affecting the centers of pain and thermoregulation; has analgesic and antipyretic effects.
Phenylephrine
- alpha-adrenergic agonist with moderate vasoconstrictor effect. Reduces swelling and hyperemia of the mucous membranes of the upper respiratory tract and paranasal sinuses.
Pheniramine
- blocker of H1-histamine receptors.
Has an antiallergic effect: eliminates itching of the eyes, nose and throat, swelling and hyperemia of the mucous membranes of the nasal cavity, nasopharynx and paranasal sinuses, reduces exudative manifestations. Caffeine
has a stimulating effect on the central nervous system, enhances the effect of analgesics, eliminates drowsiness and fatigue, increases physical and mental performance, reduces fatigue and drowsiness.
Ascorbic acid (vitamin C)
participates in the regulation of redox processes, carbohydrate metabolism, blood clotting, tissue regeneration, and the synthesis of steroid hormones; reduces vascular permeability and increases the body's resistance to various adverse environmental factors.
Drug interactions
Oral contraceptives and hormone replacement therapy.
Ascorbic acid acts as a competitive inhibitor for sulfated ethinyl estradiol. It was noted that ascorbic acid at a dose of 1 g increases the bioavailability of ethinyl estradiol by 60-70% in women receiving a single oral dose, by 47% with long-term use of contraceptives and by 21% in postmenopausal women receiving transdermal estradiol.
Iron.
The use of ascorbic acid may increase iron absorption. Ascorbic acid enhances iron absorption due to the formation of a chelate with oxidized iron at acidic pH, which remains soluble at alkaline duodenal pH.
Deferoxamine.
The combined use of ascorbic acid and deferoxamine in severe chronic iron intoxication can lead to impaired cardiac function. Presumably, the effect results from deferoxamine increasing the amount of iron available to chelate with ascorbic acid.
MAO inhibitors.
Enhances the effects of MAO inhibitors, sedatives, ethanol.
When taken with digoxin or other cardiac glycosides
the risk of developing arrhythmia and myocardial infarction may increase.
Antidepressants, antiparkinsonian drugs, antipsychotic drugs, phenothiazine derivatives
increase the risk of developing urinary retention, dry mouth, and constipation.
GKS
increase the risk of developing glaucoma.
Microsomal oxidation inhibitors (cimetidine)
reduce the risk of hepatotoxicity.
Metoclopramide and domperidone
increase, and
cholestyramine
reduces the rate of absorption of paracetamol.
Paracetamol reduces the effectiveness of diuretic and uricosuric drugs.
When administered simultaneously with barbiturates, diphenin, carbamazepine, rifampicin and other inducers of microsomal liver enzymes
the risk of developing hepatotoxic effects of paracetamol increases.
Most patients taking warfarin
infrequent use of paracetamol usually has little or no effect on the INR. However, with prolonged regular use, paracetamol enhances the effect of indirect anticoagulants (warfarin and other coumarin derivatives), which increases the risk of bleeding.
A single large dose of caffeine increases lithium
kidneys. Abrupt cessation of caffeine may result in increased serum lithium concentrations.
When taken simultaneously with MAO inhibitors, furazolidone
, pheniramine can lead to hypertensive crisis, agitation, and hyperpyrexia.
When taken with MAO inhibitors, phenylephrine can lead to an increase in blood pressure. Phenylephrine reduces the effectiveness of beta-blockers and antihypertensive drugs
, and also reduces the hypotensive effect
of guanethidine
, which, in turn, enhances the alpha-adrenomimetic activity of phenylephrine.
Tricyclic antidepressants
enhance the adrenomimetic effect of phenylephrine; simultaneous administration
of halothane
increases the risk of developing ventricular arrhythmia.
Dosage regimen
Inside.
Pour the contents of 1 sachet (bag) into a glass, add hot water, stir until completely dissolved and drink (you can add sugar or honey if desired). Taking the drug is recommended 1-2 hours after eating.
Adults and children over 15 years of age:
take 1 sachet 3-4 times a day with intervals between doses of 4-6 hours.
The maximum daily dose is 4 sachets.
The course of treatment without consulting a doctor is no more than 5 days.
Overdose
In case of overdose, consult a doctor immediately. Prompt medical attention is critical even if no signs or symptoms are observed.
Ascorbic acid
Symptoms of acute overdose:
diarrhea and other gastrointestinal disorders.
Symptoms of chronic intoxication with ascorbic acid:
impaired excretory function of the kidneys, formation of kidney stones, decreased capillary permeability (possible deterioration of tissue trophism, increased blood pressure, hypercoagulation, development of microangiopathies, impaired iron metabolism), erosion of tooth enamel.
Caffeine
Symptoms of acute overdose:
abdominal pain, nausea, vomiting, fever, chills, headache, agitation, insomnia, irritability, loss of appetite, weakness, tremor, anxiety, state of altered consciousness, delirium, hallucinations, increased blood pressure followed by hypotension, tachycardia, tachypnea, hypokalemia, hyponatremia , hyperglycemia, metabolic acidosis, epileptic seizures, convulsions, myoclonus and rhabdomyolysis, supraventricular and ventricular arrhythmias.
Symptoms of chronic caffeine intoxication (“caffeinism”):
irritability, insomnia, anxiety, emotional lability, chronic abdominal pain.
Pheniramine
Symptoms:
CNS depression, hyperthermia, anticholinergic syndrome (mydriasis, flushing, fever, dry mouth, urinary retention, intestinal paresis), tachycardia, hypotension, hypertension, nausea, vomiting, psychomotor agitation, disorientation, hallucinations, psychosis, convulsions, arrhythmias . Rarely, patients with agitation, seizures, or comatose patients develop rhabdomyolysis and renal failure.
Phenylephrine
Symptoms:
headache, nausea, vomiting, irritability, agitation, insomnia, psychosis, convulsions, palpitations, tachycardia, increased blood pressure, reflex bradycardia.
Paracetamol
Symptoms
appear after taking more than 7.5-10 g: during the first 24 hours after taking - pallor of the skin, nausea, vomiting, anorexia, abdominal pain, increased prothrombin time, impaired glucose metabolism, hypokalemia, metabolic acidosis (including lactic acidosis) . Symptoms of liver dysfunction may appear 12-48 hours after an overdose: increased activity of liver transaminases, hepatonecrosis. In severe cases - liver failure with progressive encephalopathy, coma. Rarely, liver failure develops rapidly and can be complicated by renal failure (tubular necrosis).
The threshold for overdose may be lowered in elderly patients and children, in patients taking certain medications (eg, liver microsomal enzyme inducers), alcohol, or who are malnourished.
From the circulatory system:
an overdose of paracetamol in people with glucose-6-phosphate dehydrogenase deficiency can cause hemolytic anemia.
Treatment:
gastric lavage, administration of activated charcoal in the first 6 hours after an overdose, administration of SH-group donors and precursors for the synthesis of glutathione - methionine 8-9 hours after an overdose and acetylcysteine - after 12 hours. The need for additional therapeutic measures (further administration of methionine and acetylcysteine ) depends on the concentration of paracetamol in the blood, as well as on the time elapsed after its administration. Symptomatic therapy.
Side effect
Allergic reactions:
skin rash, itching, urticaria, angioedema, anaphylactic shock.
From the nervous system:
headache, dizziness, drowsiness, difficulty falling asleep, increased excitability.
From the cardiovascular system:
increased blood pressure, tachycardia, palpitations.
From the digestive system:
nausea, vomiting, epigastric pain, dyspepsia, diarrhea, hepatotoxic effect.
From the senses:
mydriasis, accommodation paresis, increased intraocular pressure.
From the hematopoietic organs:
anemia, thrombocytopenia, agranulocytosis, hemolytic anemia, aplastic anemia, methemoglobinemia, pancytopenia, leukopenia.
From the urinary system:
nephrotoxicity (renal colic, glycosuria, interstitial nephritis, papillary necrosis), difficulty urinating.
Other:
dryness of the oral and nasal mucosa, pharyngitis, bronchospasm.
From the skin: serious skin reactions
very rarely - acute generalized exanthematous pustulosis (AGEP; an acute condition with the development of pustular rashes; characterized by fever and diffuse erythema, accompanied by burning and itching; swelling of the face, hands and mucous membranes may occur), Stevens-Johnson syndrome (SJS; malignant exudative erythema; severe a form of erythema multiforme, in which blisters appear on the mucous membrane of the mouth, throat, eyes, genitals, and other areas of the skin and mucous membranes), toxic epidermal necrolysis (TEN, Lyell's syndrome; the syndrome is a consequence of extensive apoptosis of keratinocytes, which leads to extensive detachment areas of the skin at the dermoepidermal junction; the affected skin looks like it has been scalded with boiling water).
Adverse reactions identified during post-registration use of the drug were classified as follows: very often (≥1/10), often (≥1/100 and <1/10), infrequently (≥1/1000 and <1/100), rare (1/10,000 and <1/1000), very rare (<1/10,000).
Isolated reports of unspecified frequency (frequency of occurrence cannot be estimated from available data)
From the immune system:
very rarely - anaphylactic reactions, hypersensitivity.
Allergic reactions:
very rarely - skin rash, itching, urticaria.
From the nervous system:
very rarely - insomnia, anxiety, headache.
From the cardiovascular system:
very rarely - palpitations, tachycardia.
From the digestive system:
very rarely - increased levels of transaminases*.
* A slight increase in transaminase levels may be observed in some patients using paracetamol in recommended doses; this elevation is not associated with liver failure and usually resolves with continued treatment or discontinuation of paracetamol.
If one of the side effects described above develops, the patient should stop taking the drug and consult a doctor immediately.
special instructions
During the treatment period you should refrain from drinking alcohol.
If symptoms worsen or persist for more than 5 days, or if new symptoms appear, you should consult your doctor.
The drug may cause drowsiness.
The drug contains sucrose, which must be taken into account by patients suffering from diabetes mellitus, as well as those on a hypocaloric diet. 1 single dose of the drug contains from 2915 to 3136 mg of sucrose, which corresponds to 0.24-0.26 XE.
Keep out of the reach of children. If the drug is swallowed by a child, seek immediate medical attention.
If the medicine has become unusable or has expired, do not throw it into wastewater or onto the street!
Place the medicine in a bag and place it in the trash. These measures will help protect the environment. Effect on the ability to drive vehicles and machinery
The drug may cause drowsiness. During the treatment period, it is necessary to refrain from driving vehicles and engaging in other potentially hazardous activities that require increased concentration.
Storage conditions
The drug should be stored in a dry place, out of reach of children, at a temperature not exceeding 25°C.
Best before date
Shelf life: 3 years.
Use during pregnancy and breastfeeding
Restrictions during pregnancy - Contraindicated. Restrictions during breastfeeding - Contraindicated. Due to the lack of clinical data, the safety of the drug during pregnancy and breastfeeding has not been established, therefore the use of the drug in this category of patients is contraindicated.
Use for renal impairment
Restrictions for impaired renal function - With caution.
The drug should be used with caution in case of renal failure.
Use for liver dysfunction
Restrictions for liver dysfunction - With caution.
The drug should be used with caution in case of liver failure.
Use in elderly patients
Restrictions for elderly patients - Use with caution.
Use in children
Restrictions for children - Contraindicated.
Contraindicated in children under 15 years of age
Terms of sale
The drug is approved for use as a means of OTC.
Contacts for inquiries
JOHNSON & JOHNSON LLC (Russia)
"JOHNSON & JOHNSON" LLC group of companies Johnson & Johnson
121614 Moscow st. Krylatskaya, 17, bldg. 2 Tel Fax
Rinzasip powder for children, raspberry 10 pack
In case of overdose, consult a doctor immediately. Prompt medical attention is critical, even if you do not experience any signs or symptoms. Pheniramine: Symptoms: convulsions, impaired consciousness, coma.
Paracetamol:
Symptoms (mainly caused by paracetamol), in adults and children over 12 years of age, appear after taking more than 7.5 - 10 g within 8 hours. Fatalities are rare (less than 3-4% of untreated cases) and occur with doses >15 g of paracetamol. In children under 12 years of age, acute overdose of >150 mg/kg paracetamol is not associated with hepatotoxicity. During the first 24 hours after administration - anorexia, nausea, vomiting, abdominal pain, increased sweating, pallor and general malaise.
Symptoms of liver dysfunction may appear 12-48-72 hours after an overdose: increased activity of “liver” transaminases, hepatonecrosis. In severe cases - liver failure with progressive encephalopathy, coma. Rarely, liver failure develops rapidly and can be complicated by renal failure (tubular necrosis). In case of overdose with a slow-release paracetamol preparation, it is advisable to additionally determine the concentration of paracetamol in plasma 4-6 hours after determining the initial concentration of paracetamol in plasma. Severe hepatotoxicity or death has been extremely rare during acute paracetamol overdose in young children, possibly due to differences in the metabolic pathways of paracetamol.
The following are clinical events associated with paracetamol overdose that, when considered in relation to overdose, are expected, including death due to fulminant liver failure or its sequelae.
The following clinical consequences of acute liver failure caused by an overdose of paracetamol (in adults and adolescents over 12 years of age, taking > 7.5 g paracetamol over 8 hours, in children under 12 years, taking > 150 mg/kg paracetamol over 8 hours) are expected: sepsis, fungal infection, bacterial infection, disseminated intravascular coagulation, coagulopathies, thrombocytopenia, hypoglycemia, metabolic acidosis, lactic acidosis, coma, encephalopathy, cerebral edema, cardiomyopathy, hypotension, respiratory failure, pancreatitis, gastrointestinal bleeding, acute renal failure ( tubular necrosis), multiple organ failure.
The threshold for overdose may be lowered in children, in patients taking certain medications (eg, liver microsomal enzyme inducers), alcohol, or who are malnourished.
Treatment: gastric lavage, administration of activated carbon in the first 6 hours after an overdose, administration of SH-group donors and precursors for the synthesis of glutathione - methionine 8 - 9 hours after an overdose and acetylcysteine after 12 hours. The need for additional therapeutic measures (further administration of methionine and acetylcysteine) is determined by the concentration of paracetamol in the blood, as well as the time elapsed after its administration. Symptomatic therapy.
Rinzasip
Rinzasip (paracetamol + phenylephrine + pheniramine + caffeine) is a combined Indian drug for symptomatic (directed at the effect, not the cause) treatment of acute respiratory diseases, more often popularly referred to as “colds”. The action of rinzasip is determined by the quartet of active ingredients included in its composition, each of which is worthy of a separate presentation. The non-narcotic analgesic-antipyretic paracetamol has an analgesic and antipyretic effect: it can effectively relieve the pain syndrome characteristic of colds (sore and sore throat, headaches, joint and muscle pain) and reduce elevated body temperature. The sympathomimetic phenylephrine has a vasoconstrictor effect on peripheral blood vessels, relieves swelling and reduces hyperemia of the mucous membrane of the upper respiratory tract and sinuses. The H1-histamine receptor blocker pheniramine successfully copes with allergic manifestations: it eliminates burning and itching, and also reduces swelling and hyperemia of the mucous membranes of the nasal cavity, eyes, and sinuses. A pleasant bonus to the action of pheniramine is the elimination of the phenomenon of exudation, which prevents the development of inflammation. Caffeine has a stimulating effect on the central nervous system, which is clinically manifested by an increase in mental and physical performance, as well as a decrease in drowsiness.
Rinzasip is available in the form of powders for the preparation of a solution for oral administration. According to general recommendations, the drug is taken 1 sachet 3-4 times a day, with 4-6 hour intervals between doses. The maximum daily therapeutic “threshold” is 4 sachets per day. The duration of the medication course should not exceed 4-5 days. The optimal time to take is 1-2 hours after a meal, along with a sufficient amount of liquid. Method of preparing the solution: the contents of 1 sachet are dissolved in a glass of hot water and stirred vigorously until the powder is completely dissolved. You can add sugar or honey to taste.
The use of Rinzasip imposes certain restrictions on patients. Thus, during treatment you should refrain from consuming ethanol in any form, as well as anxiolytic (“anti-anxiety”) drugs. The combined use of drugs containing paracetamol is not allowed (rinzasip already contains it, so additional addition of this substance to the pharmacological “diet” may increase the risk of side effects). If the patient's condition does not improve after 3-5 days of pharmacotherapy, a mandatory medical consultation is necessary. Combining rinzasip with antiparkinsonian drugs, antidepressants, and antipsychotic drugs can cause problems with diuresis, constipation, and hyposalivation. When rinzasip is used together with glucocorticosteroids, the risk of developing glaucoma increases. Paracetamol contained in the drug may reduce the effectiveness of diuretics. Tricyclic antidepressants (imipramine, desipramine, amitriptyline) potentiate the adrenomimetic effect of phenylephrine.
It is no secret that combined soluble powders for relieving cold symptoms are among the most popular drugs among the population, especially in the autumn-winter period. Over-the-counter medications, such as Rinzasip, often contain different doses of the same pharmacologically active ingredients. But the effectiveness of the drug is largely determined by the doses of the active substances included in its composition. Thus, the same paracetamol is a “regular” of many anti-cold combinations and one of the safest analgesics-antipyretics: not all drugs its dose corresponds to the dose recommended by WHO (0.5–1 g for 4 “daily” doses, which is equivalent to daily 2–4 g). Rinzasip is one of those drugs that meets WHO recommendations for paracetamol content. It, along with Grippoflu, Coldrex, Maxicold, Rinicold, is one of the most affordable.
